Terms: = Endocrine gland cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Treatment
191 results:
1. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
[TBL] [Abstract] [Full Text] [Related]
2. Small-molecule inhibitor HI-TOPK-032 improves NK-92MI cell infiltration into ovarian tumours.
Deng M; Yang R; Sun Q; Zhang J; Miao J
Basic Clin Pharmacol Toxicol; 2024 May; 134(5):629-642. PubMed ID: 38501576
[TBL] [Abstract] [Full Text] [Related]
3. Infiltration of CD3+ and CD8+ lymphocytes in association with inflammation and survival in pancreatic cancer.
Tushoski-Alemán GW; Herremans KM; Underwood PW; Akki A; Riner AN; Trevino JG; Han S; Hughes SJ
PLoS One; 2024; 19(2):e0297325. PubMed ID: 38346068
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
Amaria R; Knisely A; Vining D; Kopetz S; Overman MJ; Javle M; Antonoff MB; Tzeng CD; Wolff RA; Pant S; Lito K; Rangel K; Fellman B; Yuan Y; Lu KH; Sakellariou-Thompson D; Haymaker CL; Forget MA; Hwu P; Bernatchez C; Jazaeri AA
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309721
[TBL] [Abstract] [Full Text] [Related]
5. Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Verdegaal EME; Santegoets SJ; Welters MJP; de Bruin L; Visser M; van der Minne CE; de Kok PM; Loof NM; Boekestijn S; Roozen I; Westra IM; Meij P; Van der Burg SH; Kroep JR
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37949617
[TBL] [Abstract] [Full Text] [Related]
6. Overcoming immune checkpoint blockade resistance in solid tumors with intermittent ITK inhibition.
Zhao M; Li L; Kiernan CH; Castro Eiro MD; Dammeijer F; van Meurs M; Brouwers-Haspels I; Wilmsen MEP; Grashof DGB; van de Werken HJG; Hendriks RW; Aerts JG; Mueller YM; Katsikis PD
Sci Rep; 2023 Sep; 13(1):15678. PubMed ID: 37735204
[TBL] [Abstract] [Full Text] [Related]
7. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids.
Beelen NA; Aberle MR; Bruno V; Olde Damink SWM; Bos GMJ; Rensen SS; Wieten L
Front Immunol; 2023; 14():1133796. PubMed ID: 37520563
[TBL] [Abstract] [Full Text] [Related]
8. ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
Herzog TJ; Hays JL; Barlin JN; Buscema J; Cloven NG; Kong LR; Tyagi NK; Lanneau GS; Long BJ; Marsh RL; Seward SM; Starks DC; Welch S; Moore KN; Konstantinopoulos PA; Gilbert L; Monk BJ; O'Malley DM; Chen X; Dalal R; Coleman RL; Sehouli J
Future Oncol; 2023 Jul; 19(23):1577-1591. PubMed ID: 37334673
[TBL] [Abstract] [Full Text] [Related]
9. Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer.
Kumar P; Ranmale S; Mehta S; Tongaonkar H; Patel V; Singh AK; Mania-Pramanik J
J Ovarian Res; 2023 Jun; 16(1):114. PubMed ID: 37322531
[TBL] [Abstract] [Full Text] [Related]
10. Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer.
Koh EK; Lee HR; Son WC; Park GY; Kim J; Bae JH; Park YS
Sci Rep; 2023 May; 13(1):7656. PubMed ID: 37169953
[TBL] [Abstract] [Full Text] [Related]
11. Effects of leptin on the viability of human ovarian cancer cells and changes in cytokine expression levels.
Dincer F; Atmaca H; Akman L; Oktay LM; Karaca B; Terek MC
PeerJ; 2023; 11():e15246. PubMed ID: 37155466
[TBL] [Abstract] [Full Text] [Related]
12. Simultaneous targeting of PD-1 and il-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis.
Piper M; Hoen M; Darragh LB; Knitz MW; Nguyen D; Gadwa J; Durini G; Karakoc I; Grier A; Neupert B; Van Court B; Abdelazeem KNM; Yu J; Olimpo NA; Corbo S; Ross RB; Pham TT; Joshi M; Kedl RM; Saviola AJ; Amann M; Umaña P; Codarri Deak L; Klein C; D'Alessandro A; Karam SD
Cancer Cell; 2023 May; 41(5):950-969.e6. PubMed ID: 37116489
[TBL] [Abstract] [Full Text] [Related]
13. Analysis of the Occurrence of Predicative Factors of Chronic Fatigue in Female Patients with cancer of the Reproductive Organs with Respect to Stage of treatment.
Kłysiak M; Wieder-Huszla S; Branecka-Woźniak D; Karakiewicz-Krawczyk K; Napieracz-Trzosek I; Owsianowska J; Jurczak A; Cymbaluk-Płoska A
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36834426
[TBL] [Abstract] [Full Text] [Related]
14. Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review.
Persano I; Parlagreco E; La Salvia A; Audisio M; Volante M; Buttigliero C; Scagliotti GV; Brizzi MP
Semin Oncol; 2022 Dec; 49(6):476-481. PubMed ID: 36759234
[TBL] [Abstract] [Full Text] [Related]
15. TGF-β2 antisense oligonucleotide enhances T-cell mediated anti-tumor activities by il-2 via attenuation of fibrotic reaction in a humanized mouse model of pancreatic ductal adenocarcinoma.
Lee HK; Nam MW; Go RE; Koo J; Kim TH; Park JE; Choi KC
Biomed Pharmacother; 2023 Mar; 159():114212. PubMed ID: 36610224
[TBL] [Abstract] [Full Text] [Related]
16. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer.
Heiduk M; Plesca I; Glück J; Müller L; Digomann D; Reiche C; von Renesse J; Decker R; Kahlert C; Sommer U; Aust DE; Schmitz M; Weitz J; Seifert L; Seifert AM
JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36509285
[TBL] [Abstract] [Full Text] [Related]
17. Mesothelin CAR-T cells secreting PD-L1 blocking scFv for pancreatic cancer treatment.
Wang Y; Fang X; Li M; Ye J; Zhao S; Yu L; Wang J; Wang Y; Yan Z
Cancer Genet; 2022 Nov; 268-269():103-110. PubMed ID: 36288641
[TBL] [Abstract] [Full Text] [Related]
18. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4.
Hao S; Xu S; Li L; Li Y; Zhao M; Chen J; Zhu S; Xie Y; Jiang H; Zhu J; Wu M
BMC Cancer; 2022 Oct; 22(1):1092. PubMed ID: 36284271
[TBL] [Abstract] [Full Text] [Related]
19. The influence of thyroid hormone medication on intra-therapeutic half-life of
Happel C; Kranert WT; Bockisch B; Sabet A; Grünwald F; Groener D
Sci Rep; 2022 Aug; 12(1):13925. PubMed ID: 35978004
[TBL] [Abstract] [Full Text] [Related]
20. Herpesvirus entry mediator regulates the transduction of Tregs via STAT5/Foxp3 signaling pathway in ovarian cancer cells.
Shan Y; Zhang B; Chen L; Zhang H; Jiang C; You Q; Li Y; Han H; Zhu J
Anticancer Drugs; 2023 Jan; 34(1):73-80. PubMed ID: 35946515
[TBL] [Abstract] [Full Text] [Related]
[Next]